During the past decade, Nantong Tumor Hospital conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 2 clinical trials were completed, i.e. on average, 4.3% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 2 clinical trials were completed. i.e. 7.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nantong Tumor Hospital" #1 sponsor was "BeiGene" with 4 trials, followed by "Pfizer" with 3 trials sponsored, "Beijing Shenogen Biomedical Co., Ltd" with 2 trials sponsored, "Betta Pharmaceuticals Co., Ltd." with 2 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 2 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nantong Tumor Hospital" #1 collaborator was "The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China" with 5 trials as a collaborator, "Anhui Provincial Hospital" with 3 trials as a collaborator, "Peking University Cancer Hospital & Institute" with 3 trials as a collaborator, "The First Affiliated Hospital of Anhui Medical University" with 3 trials as a collaborator and "The First Affiliated Hospital of Zhengzhou University" with 3 trials as a collaborator. Other collaborators include 128 different institutions and companies that were collaborators in the rest 120 trials.

According to Clinical.Site data, the most researched conditions in "Nantong Tumor Hospital" are "Non-small Cell Lung Cancer" (4 trials), "Non-Small Cell Lung Cancer" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Hepatocellular Carcinoma (HCC)" (2 trials) and "Prostate Cancer" (2 trials). Many other conditions were trialed in "Nantong Tumor Hospital" in a lesser frequency.

Most popular intervention types in "Nantong Tumor Hospital" are "Drug" (43 trials), "Other" (3 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Tislelizumab" (5 trials), "Amivantamab" (2 trials), "Bevacizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nantong Tumor Hospital" are 42 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are 30 active trials in "Nantong Tumor Hospital". 1 are not yet recruiting, 16 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in Nantong Tumor Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Nantong Tumor Hospital, 3 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".